Journals / Erciyes Medical Journal / 2020 / Cilt: 42 - Sayı: 4

Appearance of COVID-19 Pandemic in a Rheumatology Clinic in Turkey

Pages
359–361
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

A severe form of the disease usually occurs in immunosuppressed patients, as well as elderly patients (>60 years of age) and patients with comorbidities (4, 5).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Coronavirus disease 2019 (COVID-19) is a disease that may cause acute respiratory illnesses in humans with high contagiousness.
📊
Key Findings & Data:Having originated in Wuhan city of China in December 2019 and being a member of coronaviridae family, the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has been defined as one of the causes of pneumonia (1).
💡
Conclusion & Impact:A severe form of the disease usually occurs in immunosuppressed patients, as well as elderly patients (>60 years of age) and patients with comorbidities (4, 5).
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

Coronavirus disease 2019 (COVID-19) is a disease that may cause acute respiratory illnesses in humans with high contagiousness. Having originated in Wuhan city of China in December 2019 and being a member of coronaviridae family, the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has been defined as one of the causes of pneumonia (1). According to the data from China, where the disease was first seen, 80% of the people who contract the virus shake it off with minor cold-like symptoms. On the other hand, 20% of the patients require hospitalization, while 5–15% of the patients require intensive care (2). The exact number of patients infected remains unknown; however, the mortality rate is estimated at approximately 1–4% (3). The most common causes of mortality in these patients were found to be interstitial pneumonia and acute respiratory distress syndrome (ARDS) induced by diffuse alveolar damage. A severe form of the disease usually occurs in immunosuppressed patients, as well as elderly patients (>60 years of age) and patients with comorbidities (4, 5).

🔖

Cite This Article

KOZ, G., NAS, K. (2022). Appearance of COVID-19 Pandemic in a Rheumatology Clinic in Turkey. Erciyes Medical Journal, Cilt: 42 - Sayı: 4, 359–361. https://ajindex.com/articles/502312

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Özdemir Ö. Coronavirus Disease 2019 (COVID-19): Diagnosis and Management. Erciyes Med J 2020; 42(3): 242–7
  2. Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia. Radiology. February 13, 2020:200370. doi: 10.1148/radiol.2020200370. [Ahead of Print] 3. Lipsitch M, Swerdlow DL, Finelli L. Defining the Epidemiology of Covid-19 - Studies Needed. N Engl J Med 2020; 382(13): 1194–6
  3. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020; 323(11): 1061–9
  4. Baddal B. Importation and Transmission Routes of COVID-19 into Northern Cyprus: Considerations and Challenges. Erciyes Med J 2020; 42(3): 333–5
  5. Accortt NA, Lesperance T, Liu M, Rebello S, Trivedi M, Li Y, et al. Impact of sustained remission on the risk of serious infection in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2018; 70(5): 679–84
  6. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford) 2013; 52(1): 53–61
  7. Tudesq JJ, Cartron G, Rivière S, Morquin D, Iordache L, Mahr A, et al. Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and/or malignant hematological disorders. Autoimmun Rev 2018; 17(2): 115–24
  8. Edwards CJ, Galeazzi M, Bellinvia S, Ringer A, Dimitroulas T, Kitas G. Can we wean patients with inflammatory arthritis from biological therapies?. Autoimmun Rev 2019; 18(12): 102399
  9. Coletto LA, Favalli EG, Caporali R. Psoriasis and psoriatic arthritis: How to manage immunosuppressants in COVID-19days. Dermatol Ther. 2020 Apr 14:e13415. doi: 10.1111/dth.13415. [Epub ahead of print] 11. Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: Faraway, so close!. Autoimmun Rev 2020; 19(5): 102523.